Objectives
To evaluate the effectiveness of antibiotics for bronchiolitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2010, issue 4) , which includes the Cochrane Acute Respiratory Infection Group's Specialised Register, and the Database of Abstracts of Reviews of Effects, MEDLINE (January 1966 to November 2010 , EMBASE (1990 to December 2010 ) and Current Contents (2001 to December 2010 .
Selection criteria
Randomised controlled trials (RCTs) comparing antibiotics to placebo in children under two years diagnosed with bronchiolitis, using clinical criteria (including respiratory distress preceded by coryzal symptoms with or without fever). Primary clinical outcomes included time to resolution of signs or symptoms (pulmonary markers included respiratory distress, wheeze, crepitations, oxygen saturation and fever). Secondary outcomes included hospital admissions, length of hospital stay, re-admissions, complications or adverse events and radiological findings.
Data collection and analysis
Two review authors independently analysed the search results.
Main results
Five studies (543 participants) met our inclusion criteria. One study randomised 52 children to either ampicillin or placebo and found no significant difference between the two groups for length of illness. A small study (21 children) with higher risk of potential bias randomised children with proven RSV infection to clarithromycin or placebo and found clarithromycin may reduce hospital readmission (8% antibiotics versus 44% placebo; Fishers exact; P = 0.081). The two studies (267 children) providing adequate data for length of hospital stay showed no difference between antibiotics and control (pooled mean difference 0.34; 95% CI -0.71 to 1.38). Two studies randomised children to intravenous ampicillin, oral erythromycin and control and found no difference for most symptom measures. None of the trials reported deaths.
Authors' conclusions
This review found minimal evidence to support the use of antibiotics for bronchiolitis. Research to identify a possible small subgroup of patients who have complications from bronchiolitis such as respiratory failure and who may benefit from antibiotics is justified.
P L A I N L A N G U A G E S U M M A R Y

Antibiotics for bronchiolitis in babies
Bronchiolitis is a serious respiratory illness that often affects young babies. It is most commonly caused by respiratory syncytial virus (RSV) and is the most common reason for hospitalisation in babies under the age of six months. Babies usually present with runny nose, cough, shortness of breath and signs of respiratory distress which can become life-threatening. Despite its viral cause, antibiotics are prescribed in 34% to 99% of cases. Prescribers may be expecting benefits from anti-inflammatory effects attributed to some antibiotics or be concerned about secondary bacterial infection, particularly in children who are very unwell and require intensive care admission.
This systematic review found five trials (543 participants) comparing antibiotics with placebo or no antibiotics. Two of these also compared intravenous and oral antibiotics. Two trials showed that antibiotics are no better than placebo at reducing the length of illness of bronchiolitis and hospitalisation. Two more recent studies comparing antibiotics with no antibiotics found no improvement in the length of illness or hospitalisation. One smaller, poorer quality trial found benefit for antibiotics over placebo for some outcomes. Only one of the five included trials had a low risk of bias. Antibiotics may be justified in children who are very unwell and requiring intensive care admission. Antibiotics need to be used cautiously owing to the potential for side effects, cost to the patient and the community and increasing bacterial resistance to antibiotics.
B A C K G R O U N D Description of the condition
Bronchiolitis is a serious, potentially life-threatening respiratory illness that often affects young babies. It occurs most frequently in the first year of life and is the commonest cause of hospital admissions in infants under six months of age (Wohl 1978) . The most commonly identified pathogen is respiratory syncytial virus (RSV). Other viruses such as human meta-pneumovirus (HMPV), influenza, parainfluenza, adenovirus and rhinovirus have also been implicated (Williams 2004) . Other less common pathogens include Mycoplasma pneumoniae (M. pneumoniae) which can occur in sporadic outbreaks (Glezen 1971; Rose 1987) . The diagnosis is most often made on clinical grounds, which usually includes tachypnoea and wheezing in children under two years of age (Bordley 2004) . Immunofluorescence and culture of the nasopharyngeal aspirate may be used to determine the causative organism and may reduce antibiotic use (Christakis 2005) . A chest Xray may show hyperinflation and patchy atelectasis (Smyth 2006) . There are few effective therapies, including antiviral therapies (Smyth 2006) .
Description of the intervention
Antibiotics are not recommended unless there is concern about complications such as secondary bacterial pneumonia (Fitzgerald 2004; Lozano 2002) . This is based on evidence suggesting a low risk of bacteraemia (0.2%) in children with bronchiolitis and fever -a lower risk than for children with a fever without a recognisable illness, where the rate ranges from 2% to 7% (Greenes 1999) . Antibiotic use comes with significant harms including common adverse reactions (rash, abdominal pain, diarrhoea and vomiting), cost and community bacterial resistance (Brook 1998 
How the intervention might work
Antibiotics may be useful in cases of illness where superinfection with bacteria occurs, although it is unlikely that antibiotics will be effective for a condition that only has a viral cause. However, some antibiotics may have anti-inflammatory effects which may improve symptoms.
Why it is important to do this review
The use of antibiotics for uncomplicated bronchiolitis is common yet is not justified by our understanding of bronchiolitis as a viral illness. The discord between clinical practice and the pathophysiological understanding of bronchiolitis as a viral illness will benefit from the empirical evidence offered by this systematic review.
O B J E C T I V E S
The objective of this review is to evaluate clinical outcomes resulting from the use of antibiotics for bronchiolitis in children compared to placebo or other interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Single or double-blind randomised controlled trials (RCTs) comparing antibiotics to placebo or control to treat bronchiolitis.
Types of participants
Children under the age of two years diagnosed with bronchiolitis using clinical criteria, such as respiratory distress preceded by coryzal symptoms, with or without fever.
Types of interventions
Oral, intravenous, intramuscular or inhaled antibiotics versus placebo.
Types of outcome measures Primary outcomes
Time for the resolution of symptoms/signs:
1. pulmonary markers; 2. respiratory distress; 3. wheeze; 4. crepitations; 5. oxygen saturation; and 6. fever. 
Searching other resources
We considered all languages. We handsearched the references of all identified studies. One review author (GS) and an expert librarian (LE) carried out the search. We contacted experts in the field looking for unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (GS, CDM) independently scanned abstracts from the initial search results to identify trials that loosely met the inclusion criteria. Two review authors (CDM, JD) independently reviewed the full-text articles and applied the inclusion criteria.
Data extraction and management
Two review authors (CDM, JD) independently extracted data from included studies using data extraction forms which included type of intervention, adverse events, continuous and dichotomous outcomes. We also noted the setting (hospital or primary care), study population and any additional interventions or tests.
Assessment of risk of bias in included studies
We rated the quality of each eligible RCT according to the 'Risk of bias' tool available in RevMan 5.1 (RevMan 5.1) and criteria set out in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We assessed methodological quality under the headings of allocation, blinding, incomplete outcome data, selective reporting and other potential sources of bias. Two review authors (JD, CDM) independently assessed the methodological quality of the new included trials for this review update. We resolved any disagreement between the review authors by discussion.
Measures of treatment effect
We analysed data using RevMan 5.1 (RevMan 5.1). We expressed continuous data comparisons using mean differences (MD) where there was one study or standardised mean difference (SMD) where more than one study used different measurement scales. We expressed dichotomous data using odds ratios (OR). We pooled data into clinical outcomes where multiple trial results for the same clinical presentation existed and heterogeneity did not preclude pooling of results
Unit of analysis issues
The unit of analysis for each outcome was the individual research participant. 
Dealing with missing data
Assessment of heterogeneity
We were only able to combine data for deaths and length of hospital stay. Given there were no deaths we cannot assess heterogeneity for that outcome. The two studies providing sufficient data to compare length of hospital stay gave heterogenous results.
Assessment of reporting biases
There was no evidence of publication bias nor reporting bias.
Data synthesis
We undertook meta-analysis for outcomes where there were sufficient comparable data. Only two outcomes fitted this bill: deaths and length of hospital stay. We were not able to combine symptom measures owing to a lack of comparability of outcome measures or the timing of measure was irreconcilably different. We undertook narrative synthesis of the majority of results.
Subgroup analysis and investigation of heterogeneity
Not applicable.
Sensitivity analysis
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
Initial database searching revealed the following results: 173 articles in MEDLINE, 102 articles in EMBASE, 23 articles in CEN-TRAL and two articles in DARE. Of these 300 articles, we rejected 297 on the basis of title and abstract alone leaving three studies. In this 2011 update, an additional 259 studies were identified, with 35 duplicates and 220 rejected on title and abstract alone with four studies remaining. Of the seven studies identified from initial and updated searches, two were excluded: one because it did not involve clinical criteria for inclusion (Friis 1984) and one because it did not involve an antibiotic (Boogaard 2007) . Five studies did meet inclusion criteria (Field 1966; Kabir 2009; Kneyber 2008; Mazumder 2009; Tahan 2007) .
Included studies
Field 1966 
Excluded studies
Boogaard 2007 did not study antibiotics for bronchiolitis. One study was excluded (Friis 1984) because it dealt with both pneumonia and bronchiolitis using crepitations and radiography as criteria for patient selection. The study did perform a subgroup analysis of the two groups (antibiotics and placebo) based on virological diagnosis and these results are discussed.
Risk of bias in included studies
Risk of bias is summarised in Figure 1 and Figure 2 . 
Blinding
Three studies described adequate blinding of participants (all infants), their parents and the investigators. Two did not discuss blinding (Kabir 2009; Mazumder 2009) . None of the studies described blinding of the outcome assessor.
Incomplete outcome data
In the Mazumder 2009 trial, 22 participants (out of 124) were excluded because they did not attend regular follow up (18) or were persistently unwell. In the Kabir 2009 trial, 17 children were referred to tertiary care where there was access to paediatric intensive care and for 15 children their parents withdrew or they left their respective hospitals. In Tahan 2007, nine participants were excluded because they took corticosteroids. There were only 15 participants in each group and six were excluded from the placebo group for taking corticosteroids and three from the clarithromycin group. In Field 1966, eight patients were excluded from the study owing to symptom severity (three from the ampicillin group and five from the placebo group) with an extra two participants (one from each group) lost to follow up at the end of the trial. There were no drop outs from the Kneyber 2008 trial.
Selective reporting
There are no concerns about selective reporting.
Other potential sources of bias
No other concerns were identified.
Effects of interventions Oral ampicillin versus placebo
Field 1966 randomised infants with the clinical presentation of bronchiolitis to either placebo (24 patients) or ampicillin (28 patients). The main outcome measure was length of illness. This was found to be 9.54 days in the group receiving ampicillin and 9.7 days in the group receiving placebo. This was not a significant difference as calculated by the study authors. There were insufficient data provided for us to independently confirm this. There were no deaths in either group.
One excluded study (Friis 1984) analysed separately a subgroup of children in their trial who tested positive for RSV. This trial randomised 150 children who had either fine crepitating rales or pulmonary consolidation on chest radiograph to either antibiotics (ampicillin) or no antibiotics. While this trial did not start by selecting children with a clinical presentation of bronchiolitis, the results of the subgroup analysis are relevant. In children who were RSV-positive, there was no significant difference found between the antibiotic and no antibiotic groups for the outcomes of fever, pulmonary symptoms, duration of hospital stay, otitis media or chest radiograph findings.
Oral macrolide antibiotic versus placebo
Tahan 2007 randomised infants younger than seven months admitted to a department of paediatrics in Turkey to clarithromycin for three weeks (15) or placebo (15) if they were found to be positive for an RSV immunofluorescent test. Nine participants were excluded owing to corticosteroid use leaving 12 in the clarithromycin group and nine in the placebo group. Median hospital stay on clarithromycin was 2.13 days (interquartile range: 2 to 2.83) compared to 3.67 days (3 to 4.17). One participant was readmitted in the clarithromycin group (8.3%) and four in the placebo group (44%). Duration of beta-agonist use in the clarithromycin group was five days (interquartile range: 5 to 7), for placebo seven days (5 to 7). Duration of oxygen use in the clarithromycin group was 31 hours (interquartile range: 28 to 42), for placebo 72 hours (52 to 80). Duration of intravenous fluids for the clarithromycin group was 26 hours (interquartile range: 22 to 36) and for placebo 56 hours (46 to 66). Kneyber 2008 randomised infants younger than 24 months with clinically-suspected viral bronchiolitis who were admitted to hospital in the Netherlands to azithromycin (32 children) and placebo (39 children). The primary outcome was length of hospital admission, which was 5.5 days (standard deviation (SD) 2.55) in the azithromycin group and 5.82 days (SD 2.0), resulting in a mean difference of -0.32 (95% confidence interval (CI) -1.40 to 0.76). Beta-agonists were used by 17 participants (mean duration: 2.8 days +/-0.6 standard error (SE)) in the azithromycin group and 23 participants (three days +/-0.4 SE) in the placebo group. Oxygen was used by 20 participants in the azithromycin group (mean duration: 3.8 days +/-0.4 SE) and 31 participants in the placebo group (mean duration 3.4 days +/-0.3). Other outcomes are tabled (Table 1) .
Oral macrolide antibiotic (erythromycin) versus parenteral ampicillin versus control
Mazumder 2009 randomised infants younger than 24 months (and older than one month) with clinically suspected bronchiolitis to intravenous ampicillin (29 children), oral erythromycin (32 children) and no antibiotics (43 children). Symptoms (wheeze, shortness of breath, oxygen saturation less than 96%, lack of social smile and feeding difficulties) were measured on days one, three and five. There were significantly fewer children with wheeze in the oral erythromycin group on day three but significantly fewer children with wheeze in the control group on day five. None of the other symptom measures differed significantly between the three groups. Full results as reported by this study for the three groups are tabled with Chi 2 test results and significance levels ( Table 2 ). The two antibiotic arms of this trial were also combined and compared with control. For most comparisons there was no significant difference between antibiotics and control. For the outcome of wheeze on day 3, significantly fewer children had wheeze in the antibiotics arm (OR 0.27; 95% CI 0.12 to 0.62) (Analysis 7.1). However, on day five significantly more children in the antibiotics arm had wheeze compared with control (OR 5.55; 95% CI 1.18 to 26.05) (Analysis 7.1). Kabir 2009 randomised infants younger than 24 months with clinical signs of bronchiolitis (hospitalised with runny nose, cough, breathing difficulty, chest indrawing and rhonchi on auscultation). Symptom resolution was measured as rapid (less than four days) or gradual (more than four days). None of the symptom measures differed significantly between parenteral ampicillin, oral erythromycin and control (Table 3) . Length of hospital stay did not differ significantly between parenteral ampicillin and oral erythromycin and control (Analysis 3.1).
Meta-analysis
There were no deaths in any arms of any of the five included trials. 
D I S C U S S I O N
Summary of main results
Four included studies did not find any difference between antibiotics and placebo for their primary outcomes of length of illness (Field 1966) 
Quality of the evidence
Three small RCTs have examined antibiotics versus placebo with only 72 participants in antibiotic arms and 72 participants in placebo arms. The two studies (Field 1966; Kneyber 2008) describing adequate randomisation conducted in high-income countries did not find any difference between antibiotic and placebo arms. The study which found clarithromycin more likely to reduce hospital admission than placebo did not adequately describe randomisation nor allocation concealment and 30% of those randomised were excluded owing to co-administration of corticosteroids (Tahan 2007). The inconsistency of results seems most likely to be owing to the differences in methodological quality. The study by Tahan 
Potential biases in the review process
Agreements and disagreements with other studies or reviews
Excluded studies comparing antibiotics to placebo in participants with bronchiolitis did not find any significant difference (Friis 1984).
A U T H O R S ' C O N C L U S I O N S Implications for practice
Overall, this review found conflicting results. However, the two higher quality but small studies do not support the use of antibiotics for bronchiolitis. One small study with a higher risk of potential bias supported the use of macrolide antibiotics, while two larger studies with higher risk of potential bias did not support the use of antibiotics, including macrolide antibiotics, for bronchiolitis. Antibiotics may be justified in children with bronchiolitis who have respiratory failure.
Implications for research
Research to identify a possible small subgroup of patients presenting with bronchiolitis-like symptoms who may benefit from antibiotics is justified. These might include those with respiratory failure, in intensive care, with nosocomially acquired RSV, and with cyanotic congenital heart disease. Otherwise, research may be better focused on determining the reasons for clinicians to use antibiotics so readily for bronchiolitis and therefore their use of antibiotics for bronchiolitis, as well as ways to reduce anxiety.
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